Dublin, Dec. 23, 2021 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Market Size, Share & Trends Analysis Report By Biomarker (Exosomes, CTC), By Technology (NGS, PCR Microarrays), By Sample Type, By Region (APAC, North America), and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
The global liquid biopsy market size is expected to reach USD 19.35 billion by 2028, registering a CAGR of 13.5% during the forecast period. It is a revolutionary technique that has created various opportunities that were previously unexplored.
It aids in the detection and isolation of circulating tumor DNA, exosomes, and circulating tumor cells and is a source of proteomics and genomics information in cancer patients.
Rapid development in digital Polymerase Chain Reaction (PCR) and NGS-based technology has improved the accuracy of liquid biopsy. It can be performed repeatedly for disease monitoring and is anticipated to help overcome the limitations of tissue biopsies.
As liquid biopsies are the most promising novel techniques for cancer care, established as well as emerging companies have increased their R&D to develop novel liquid biopsy solutions.
Liquid Biopsy Market Report Highlights
The Multi-gene Parallel Analysis (NGS) technology segment held the largest revenue share of the global market in 2020.
This can be attributed to rapid enhancements in NGS technology. With this technology, liquid biopsies are anticipated to gain considerable importance in cancer-related studies and research.
On the basis of sample type, blood sample-based tests dominated the market in 2020.
Blood samples can readily be taken at a more frequent interval, thus increasing the adoption rate.
Circulating Nucleic Acids are the most commonly used biomarker for liquid biopsy tests.
The factors, such as the constantly evolving pipeline of ctDNA-based liquid biopsy tests, an increasing number of commercialized products, and the potential of ctRNA in determining molecular profile have contributed to the dominance of this segment.
North America is expected to be the largest revenue-generating region by 2028 owing to a high incidence of cancer, rapid technological advancements, and the presence of key players in the region.
Key players are focused on business expansion through product launches, mergers & acquisitions, agreements, partnerships, and other growth strategies.
For instance, in June 2021, Biocept, Inc. collaborated with Quest Diagnostics to provide advanced NGS-based liquid biopsy testing for lung cancer patients.
Key Topics Covered
Market Segmentation& Scope
Penetration and Growth Prospect Mapping for Biomarker, 2020 (USD Million)
COVID-19 Impact Analysis
Liquid Biopsy Pipeline Analysis
Liquid Biopsy Pricing Analysis
Liquid Biopsy Procedure Analysis
Business Environment Analysis
SWOT Analysis; By factor (Political & Legal, Economic, and Technological)
Porter's Five Forces Analysis
Market Driver Analysis
Technological Advancements In Cancer Diagnostics To Reduce Complications Associated With Conventional Means Of Cancer Detection
Rising Preference For Minimally Invasive Form Of Cancer Diagnostics
Increase In Number Of Ongoing Trials For Development Of Liquid Biopsy Assays And Tests
Market restraint analysis
Low Abundance And Fragility Of Circulating Tumor Cells
Availability Of Other Genomic Tests For Cancer Diagnostics And Treatment
Market Deals & Strategic Alliances Analysis
Technology Business Analysis
Sample Type Business Analysis
Biomarker Business Analysis
Regional Business Analysis
Myriad Genetics, Inc.
Guardant Health, Inc.
F. Hoffmann-La Roche Ltd.
THERMO FISHER SCIENTIFIC, INC.
LUCENCE HEALTH INC.
FREENOME HOLDINGS, INC.
For more information about this report visit https://www.researchandmarkets.com/r/4umihv
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900